|
See related Agrylin cap[安閣靈 膠囊] information |
|
|
|
製造商 |
Shire |
|
代理/經銷商 |
TSPC |
|
成份 |
Anagrelide HCl |
|
適應症 |
Treatment of patients with essential thrombocythemia to reduce the elevated platelet count & the risk of thrombosis & to ameliorate associated symptoms including thrombo-hemorrhagic events. |
|
用量 |
Initially, 0.5 mg qid or 1 mg bid maintained for at least 1 week. Pediatrics Initially 0.5 mg per day is recommended. In both adult & pediatrics, adjust dosage to the lowest effective dosage required to reduce and maintain platelet count below 600,000/microlitre & ideally to the normal range. The dosage should be increased by not > 0.5 mg/day in any 1 week. Max: 10 mg/day or 2.5 mg in a single dose. |
|
過量 |
View Agrylin[安閣靈] overdosage for action to be taken in the event of an overdose. |
|
用法 |
May be taken with or without food |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Severe hepatic impairment. |
|
警告 |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Agrylin[安閣靈] detailed prescribing infomation |
|
注意事項 |
Known or suspected heart disease. Perform a pre-treatment CV exam along with close monitoring during treatment. Hepatic impairment. Pregnancy, lactation. While the platelet count is being lowered (usually during the 1st 2 weeks of treatment), blood counts (Hb, WBC), liver function (SGOT, SGPT) & renal function (serum creatinine, BUN) should be monitored. |
|
不良反應 |
Headache, palpitations, GI disturbances, asthenia, edema, dizziness, pain, dyspnea, fever, peripheral edema, rash, chest pain, tachycardia, pharyngitis, malaise, cough, paresthesia, back pain, pruritus. Serious adverse events including CHF, MI, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, cerebrovascular accident, pericarditis, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, seizure have been reported.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Effects of inotropes eg. milrinone, enoximone, amrinone, olprinone & cilostazol may be exacerbated.
View more drug interactions with Agrylin[安閣靈] |
|
儲存 |
View Agrylin[安閣靈] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Agrylin[安閣靈] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Agrylin[安閣靈] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
Shire |
|
Distributor: |
TSPC
|
|
|
|
